Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | ALPL | P05186 | 3/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627934 | 0.91 | CA12 (0.38) | CA12CA1CA9ALPLPREP | |
| SCHEMBL6604988 | 0.86 | TTK (0.37) | ALPLTTKHPGDMAPK1HSD17B10 | |
| SCHEMBL15580945 | 0.84 | CA12 (0.35) | CA12CA1CA9ALPLPREP | |
| SCHEMBL628298 | 0.76 | GRM5 (0.55) | TTK | |
| SCHEMBL20402739 | 0.74 | ALPL (0.35) | ALPLHPGDKMT2AMEN1LMNA | |
| SCHEMBL18180085 | 0.74 | CA12 (0.38) | CA12CA1CA9PREPHPGD | |
| SCHEMBL31052682 | 0.74 | ALPL (0.46) | ALPLHPGDKMT2AMEN1LMNA | |
| SCHEMBL627900 | 0.74 | GAA (0.45) | ALPLHSD17B10KMT2AMEN1 | |
| SCHEMBL10112092 | 0.74 | GSK3A (0.38) | ALPLHPGDMAPK1HSD17B10LMNA | |
| SCHEMBL2634991 | 0.73 | MAP2K4 (0.45) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1820503-B1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA SRL (IT) | 2012-02-22 | — | — | EP | disclosed |
| EP-1432416-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-7511136-B2 | Aminoindazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-03-31 | — | — | US | disclosed |
| EP-1820503-A2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | Pfizer Italia S.r.l. (IT) | 2007-08-22 | — | — | EP | disclosed |
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2004-12-16 | — | — | US | disclosed |
| EP-1432416-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028720-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K15, MAP3K3, MAP3K5 | CA12 4860/4885CA1 4425/4885CA9 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.